GlassScriptPhysician profile
Sushmita Prabhu
NPI 1396316493
$1,895.79
in general payments reported to CMS, 2019-2025
19 companies · $538 in 2025
The $538 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $91.19 · 2022: $478 · 2023: $342 · 2024: $447 · 2025: $538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,327.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $439.96 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $307.16 | 2021-2025 | Opdivo, Camzyos |
| Gilead Sciences, INC. | $136.37 | 2021-2023 | |
| Pfizer INC. | $128.54 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $125.75 | 2022-2023 | Farxiga, Breztri |
| Alnylam Pharmaceuticals INC. | $114.87 | 2025 | Onpattro |
| Bayer Healthcare Pharmaceuticals INC. | $111.20 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $107.42 | 2023-2024 | Entyvio |
| Madrigal Pharmaceuticals | $69.66 | 2025 | Rezdiffra |
| Grifols USA, LLC | $63.78 | 2024 | Gamunex-C |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.86 | 2021-2022 | |
| Karyopharm Therapeutics INC. | $50.82 | 2022-2024 | Xpovio |
| Alexion Pharmaceuticals, INC. | $42.63 | 2022-2024 | Ultomiris |
| Glaxosmithkline, LLC. | $29.03 | 2023 | Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $28.83 | 2024 | Jynarque |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $24.02 | 2025 | |
| Vifor Pharma, INC. | $22.88 | 2025 | Veltassa |
| Actelion Pharmaceuticals US, INC. | $19.05 | 2025 | Opsumit |
| Incyte Corporation | $17.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sushmita Prabhu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.